| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Amgen Inc (ETR: AMG)
Â
AMG Technical Analysis
1.5
| As on 1st Nov 2017 AMG Share Price closed @ 151.55 and we RECOMMEND Buy for LONG-TERM with Stoploss of 150.50 & Sell for SHORT-TERM with Stoploss of 152.42 we also expect STOCK to react on Following IMPORTANT LEVELS. |
Â
Â
AMG Share Price
| Open | 150.05 | Change | Price | % |
| High | 152.00 | 1 Day | 1.60 | 1.07 |
| Low | 150.05 | 1 Week | 0.00 | 0.00 |
| Close | 151.55 | 1 Month | -3.85 | -2.48 |
| Volume | 1648 | 1 Year | 15.05 | 11.03 |
| 52 Week High 172.95 | 52 Week Low 130.00 | ||||
Â
ETR Germany Most Active Stocks
| DTE | 15.31 | -2.11% |
| DBK | 14.13 | 1.29% |
| EOAN | 10.38 | 2.47% |
| CBK | 11.88 | 0.93% |
| IFX | 24.51 | 4.30% |
| LHA | 28.21 | 2.96% |
| DAI | 73.07 | 2.50% |
| BIR | 0.24 | 0.00% |
| TKA | 23.49 | 2.53% |
| MEO | 29.18 | 0.00% |
Â
ETR Germany Top Gainers Stocks
Â
ETR Germany Top Losers Stocks
Â
Â
| AMG Daily Charts |
AMG Intraday Charts |
Whats New @ Bazaartrend |
AMG Free Analysis |
|
|
Â
AMG Important Levels Intraday
| SUPPORT | 0.00 |
| SUPPORT | 0.00 |
| RESISTANCE | 153.36 |
| RESISTANCE | 152.61 |
| SUPPORT | 150.49 |
| SUPPORT | 149.74 |
| SUPPORT | 0.00 |
| SUPPORT | 0.00 |
Â
AMG Target for Month July
| 4th UP TARGET | 185.02 |
| 3rd UP TARGET | 173.77 |
| 2nd UP TARGET | 166.82 |
| 1st UP TARGET | 159.87 |
| 1st DOWN TARGET | 140.03 |
| 2nd DOWN TARGET | 133.08 |
| 3rd DOWN TARGET | 126.13 |
| 4th DOWN TARGET | 114.88 |
Â
AMG Weekly Target
| 4th UP TARGET | 0.00 |
| 3rd UP TARGET | 0.00 |
| 2nd UP TARGET | 0.00 |
| 1st UP TARGET | 0.00 |
| 1st DOWN TARGET | 0.00 |
| 2nd DOWN TARGET | 0.00 |
| 3rd DOWN TARGET | 0.00 |
| 4th DOWN TARGET | 0.00 |
Â
AMG Target for Year 2021
| 4th UP TARGET | 0 |
| 3rd UP TARGET | 0 |
| 2nd UP TARGET | 0 |
| 1st UP TARGET | 0 |
| 1st DOWN TARGET | 0 |
| 2nd DOWN TARGET | 0 |
| 3rd DOWN TARGET | 0 |
| 4th DOWN TARGET | 0 |
Â
Amgen Inc ( ETR Germany Symbol : AMG )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
Â
AMG Business Profile
Amgen Inc., a biotechnology company, discovers, develops, manufactures, and delivers human therapeutics in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine worldwide. Its principal products include Neulasta, a pegylated protein for the treatment of chemotherapy-induced febrile neutropenia; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor for treating the patients with non-myeloid malignancies; and Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis in adult patients. The companyÂ’s principal products also comprise Aranesp and EPOGEN erythropoiesis-stimulating agents for the treatment of anemia and dialysis; XGEVA and Prolia for the prevention of skeletal-related events and treatment of postmenopausal women with osteoporosis; and Sensipar/Mimpara products for use in the treatment of secondary hyperparathyroidism in CKD patients on dialysis. Its other marketed products include Nplate, a thrombopoietic compound; and Vectibix, a human monoclonal antibody. The companyÂ’s products in phase 3 clinical trial comprise Evolocumab, a human monoclonal antibody used for the treatment for dyslipidemia; Talimogene Laherparepvec for the treatment of unresected stage IIIB, IIIC, or IV melanoma; and Trebananib for the treatment of ovarian cancer. Its other product in development stage includes Ivabradine, an oral drug for chronic heart failure and stable angina in patients with elevated heart rates. The company markets its products to healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies; consumers; and pharmaceutical wholesale distributors. It has collaborative arrangements with Pfizer Inc.; Glaxo Group Limited; AstraZeneca Plc.; Takeda Pharmaceutical Company Limited; UCB; and Bayer HealthCare Pharmaceuticals Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Â
© 2005-2019 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
